Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Brand Name
Invega Trinza
Generic Name
Paliperidone Palmitate
Active Ingredient
Paliperidone PalmitateCategory
Other
Variants
4
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Invega Trinza, you must consult a qualified healthcare professional.
| 50458-606 |
| 546 mg/1.75mL | INJECTION, SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 50458-608 |
Detailed information about Invega Trinza
Paliperidone palmitate is a long-acting injectable atypical antipsychotic used to treat schizophrenia and schizoaffective disorder by balancing dopamine and serotonin levels in the brain.
Dosage for paliperidone palmitate must be individualized based on the patient's clinical response and tolerability. For the monthly formulation (Invega Sustenna) in the treatment of schizophrenia or schizoaffective disorder, the standard initiation regimen for adults is:
For the 3-month formulation (Invega Trinza), the dose is based on the previous monthly dose. For example, if a patient was stable on 117 mg monthly, the 3-month dose would be 410 mg. If they were on 234 mg monthly, the 3-month dose would be 819 mg. Similarly, the 6-month formulation (Invega Hafyera) doses are scaled up from the 3-month or monthly doses (e.g., 1,092 mg or 1,560 mg every six months).
Paliperidone palmitate is generally not approved for use in pediatric patients under the age of 18 for schizoaffective disorder. For schizophrenia, safety and effectiveness in adolescents have not been as extensively established for the long-acting injectable forms as they have for the oral formulation. Healthcare providers typically weigh the risks and benefits carefully before prescribing this to minors. Always follow the specific guidance of a pediatric psychiatrist.
Because paliperidone is primarily excreted by the kidneys, dosage adjustments are critical for patients with impaired renal function.
No dosage adjustment is typically required for patients with mild to moderate hepatic (liver) impairment (Child-Pugh Class A and B). Paliperidone has not been studied in patients with severe hepatic impairment, and caution is advised in this population.
In general, recommended dosing for elderly patients with normal renal function is the same as for younger adults. However, because elderly patients are more likely to have decreased renal function, healthcare providers often monitor kidney function closely and adjust the dose accordingly. There is also a heightened risk of side effects like orthostatic hypotension in this group.
Paliperidone palmitate must be administered by a healthcare professional. It is given as a deep intramuscular injection.
Missing a dose of a long-acting injectable can lead to a return of symptoms. If a dose is missed:
Because the medication is administered by a healthcare professional, the risk of accidental overdose is low. However, signs of overdose may include severe extrapyramidal symptoms (uncontrolled muscle movements), extreme drowsiness, rapid heartbeat, or low blood pressure. In case of suspected overdose, emergency medical services should be contacted immediately. Treatment is supportive and focuses on maintaining an airway and monitoring cardiac function.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or skip appointments without medical guidance.
Common side effects of paliperidone palmitate are often manageable but can be distressing for patients. According to clinical trial data, these include:
Paliperidone palmitate is a potent medication that requires careful clinical supervision. Patients and caregivers must be aware that this medication remains in the body for several months after the last injection. Therefore, any side effects or adverse reactions may persist long after the drug is discontinued. It is vital to maintain all scheduled appointments for monitoring and to report any new or worsening symptoms to a healthcare provider immediately.
As mandated by the FDA, paliperidone palmitate carries a prominent 'Black Box Warning' regarding its use in elderly patients. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Paliperidone palmitate is not approved for the treatment of dementia-related psychosis. Physicians must evaluate the risks and benefits of antipsychotic use in elderly populations with extreme caution, particularly those with a history of cardiovascular disease or infections.
While there are few absolute contraindications for drug combinations with paliperidone, certain drugs should be avoided due to severe risks:
Paliperidone palmitate must NEVER be used in the following circumstances:
Conditions requiring a careful risk-benefit analysis by a healthcare professional include:
According to the FDA, paliperidone palmitate is classified under a system where its use in pregnancy should only be considered if the potential benefit justifies the potential risk to the fetus.
Paliperidone is excreted in human breast milk. Because of the potential for serious adverse reactions in nursing infants (such as sedation or muscle movement issues), a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. The long-acting nature of the injection means the drug will be present in milk for months after the last dose.
Paliperidone palmitate is a psychotropic agent belonging to the chemical class of benzisoxazole derivatives. Its therapeutic mechanism is primarily attributed to its high-affinity antagonism of central dopamine D2 and serotonin 5-HT2A receptors. By blocking D2 receptors in the mesolimbic pathway, it reduces the positive symptoms of psychosis. Simultaneously, its antagonism of 5-HT2A receptors in the prefrontal cortex is thought to modulate dopamine release and improve negative symptoms while reducing the risk of extrapyramidal side effects compared to first-generation antipsychotics.
Additionally, paliperidone acts as an antagonist at alpha-1 and alpha-2 adrenergic receptors and H1 histaminergic receptors. It does not have an affinity for muscarinic or beta-adrenergic receptors. The drug's action at these various receptors explains its broad clinical profile, including its sedative and hypotensive side effects.
Paliperidone is the major active metabolite of risperidone. The pharmacodynamic activity of paliperidone palmitate is identical to that of oral paliperidone. It produces a dose-dependent increase in prolactin levels due to its D2 antagonism in the tuberoinfundibular pathway. The onset of action for the injectable form is gradual; while some receptor binding occurs within 24 hours, full therapeutic effects for schizophrenia symptoms may take several weeks to stabilize as plasma levels reach a steady state.
Common questions about Invega Trinza
Paliperidone palmitate is primarily used for the treatment of schizophrenia in adults and for the treatment of schizoaffective disorder as either a standalone therapy or in combination with other medications like mood stabilizers or antidepressants. It is a long-acting injectable medication that helps manage symptoms such as hallucinations, delusions, and disorganized thinking over extended periods. By providing a continuous release of medication into the bloodstream, it is particularly effective for patients who struggle with taking daily oral pills. Healthcare providers often prescribe it to help prevent the relapse of psychotic symptoms and reduce the need for hospitalization. It is not intended for use in elderly patients with dementia-related psychosis due to increased safety risks.
The most common side effects associated with paliperidone palmitate include injection site reactions such as pain, redness, or swelling at the deltoid or gluteal muscle. Patients also frequently report somnolence or drowsiness, especially when first starting the medication or increasing the dose. Weight gain is another common side effect, often accompanied by changes in metabolism that may affect blood sugar and cholesterol levels. Extrapyramidal symptoms, which include restlessness, muscle stiffness, and tremors, are also reported by many patients. Other common issues include dizziness, particularly when standing up, and upper respiratory tract infections. It is important to discuss any persistent side effects with a healthcare provider to manage them effectively.
It is strongly recommended that patients avoid drinking alcohol while being treated with paliperidone palmitate. Alcohol is a central nervous system depressant that can significantly enhance the sedative effects of the medication, leading to extreme drowsiness, impaired judgment, and decreased motor coordination. This combination increases the risk of accidental falls, injuries, and respiratory distress. Furthermore, alcohol can interfere with the management of the underlying psychiatric condition, potentially triggering a relapse of symptoms. Because paliperidone palmitate remains in the system for several months after an injection, the risks associated with alcohol consumption persist long after the last dose was administered. Always consult your doctor before consuming any amount of alcohol during treatment.
The safety of paliperidone palmitate during pregnancy has not been established through comprehensive clinical trials in humans. Animal studies have shown some potential for harm to the fetus at high doses, and there is a known risk for neonates to experience extrapyramidal or withdrawal symptoms if exposed during the third trimester. These symptoms in newborns can include breathing difficulties, tremors, and feeding problems. Therefore, the medication should only be used during pregnancy if the healthcare provider determines that the benefits to the mother outweigh the potential risks to the developing baby. Women who are pregnant or planning to become pregnant should discuss their treatment options with their psychiatrist immediately. There is also a pregnancy registry available to monitor the health of infants born to mothers taking atypical antipsychotics.
Paliperidone palmitate begins to release into the bloodstream shortly after the first injection, but it takes time to reach a steady therapeutic level. Most patients begin to see an improvement in their symptoms within the first week or two, particularly after the second initiation dose on Day 8. However, the full clinical effect of the medication may not be realized for several weeks or even a few months as the drug concentration stabilizes in the body. Because it is a long-acting formulation, it is designed for sustained symptom control rather than immediate relief of acute agitation. Patients are often started on oral paliperidone or risperidone first to ensure they tolerate the medication before moving to the long-acting injection. Consistency in attending scheduled injection appointments is key to maintaining its effectiveness.
You cannot stop paliperidone palmitate 'suddenly' in the traditional sense because it is a long-acting injection that stays in your body for months. If you decide to stop treatment and miss your scheduled injection, the levels of the drug in your system will slowly decline over several weeks and months. This gradual decrease can lead to a slow return of schizophrenia or schizoaffective symptoms, which may eventually result in a full relapse or psychiatric emergency. You should never decide to stop your injections without a detailed plan from your healthcare provider. If discontinuation is necessary, your doctor will monitor you closely during the months it takes for the drug to leave your system and may transition you to an alternative therapy to prevent a return of symptoms.
If you miss a scheduled injection of paliperidone palmitate, you should contact your healthcare provider immediately to reschedule. The management of a missed dose depends on how much time has passed since your last injection. If the delay is less than four weeks, the dose is usually given as soon as possible, and the monthly cycle is reset. If more than four weeks have passed, a specific re-initiation protocol involving injections in the deltoid muscle may be required to bring the medication levels back to a therapeutic range. If a significant amount of time has passed (six months or more), the entire initiation schedule starting from Day 1 may need to be repeated. Missing doses increases the risk of symptom return, so staying on schedule is vital.
Yes, weight gain is a well-documented side effect of paliperidone palmitate and other atypical antipsychotics. Clinical trials have shown that a significant percentage of patients experience a weight increase of 7% or more from their starting body weight. This weight gain is often related to increased appetite and changes in the body's metabolism of fats and sugars. Because significant weight gain can increase the risk of developing type 2 diabetes and heart disease, healthcare providers monitor weight, blood sugar, and lipid levels regularly during treatment. Patients are encouraged to follow a balanced diet and engage in regular physical activity to help manage this side effect. If weight gain becomes a major concern, your doctor may discuss alternative medications or strategies to mitigate metabolic changes.
Paliperidone palmitate can interact with several other types of medications, so it is essential to inform your doctor of all drugs you are taking. It should be used with caution alongside other centrally acting drugs, such as opioids or benzodiazepines, as this can increase sedation. Because it can lower blood pressure, it may enhance the effects of antihypertensive drugs, leading to dizziness or fainting. There are also concerns with medications that affect heart rhythm (QT prolonging drugs) and those that induce liver enzymes, like rifampin, which can lower the effectiveness of paliperidone. Conversely, it is often successfully used in combination with mood stabilizers or antidepressants for schizoaffective disorder. Your healthcare provider will review your full medication list to prevent dangerous interactions.
As of early 2024, paliperidone palmitate long-acting injections (such as Invega Sustenna, Trinza, and Hafyera) are primarily available as brand-name medications and are protected by various patents. While the oral version of paliperidone (Invega) is available as a generic, the complex technology required to create the long-acting palmitate ester suspension means that generic versions of the injections are not yet widely available in many markets. However, patent expirations vary by country, and generic versions may become available in the coming years as patents expire and other pharmaceutical companies receive regulatory approval. Patients should check with their local pharmacy or insurance provider for the most current information regarding the availability of lower-cost generic alternatives for their specific formulation.
Other drugs with the same active ingredient (Paliperidone Palmitate)
> Warning: Stop taking Paliperidone Palmitate and call your doctor immediately if you experience any of these.
Prolonged use of paliperidone palmitate requires ongoing monitoring for metabolic changes. Long-term effects may include:
Increased Mortality in Elderly Patients with Dementia-Related Psychosis:
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of 17 placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Paliperidone palmitate is NOT approved for the treatment of patients with dementia-related psychosis.
Report any unusual symptoms to your healthcare provider. Regular blood tests and physical exams are necessary to monitor for these effects.
Healthcare providers will typically require the following tests to ensure safety:
Paliperidone palmitate may impair judgment, thinking, or motor skills. Since somnolence (drowsiness) and dizziness are common side effects, patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that paliperidone therapy does not affect them adversely.
Patients should be advised to avoid alcohol while taking paliperidone palmitate. Alcohol can exacerbate the sedative effects of the medication, leading to extreme drowsiness, respiratory depression, and an increased risk of falls or accidents.
Because paliperidone palmitate is a long-acting injection, it cannot be 'stopped' quickly. If a decision is made to discontinue treatment, the medication will gradually leave the system over several months. Patients should never attempt to miss a scheduled injection without consulting their doctor, as this can lead to a rapid return of psychotic symptoms (withdrawal emergence). Tapering is usually managed by extending the interval between injections or transitioning back to oral medications under strict supervision.
> Important: Discuss all your medical conditions, including any heart rhythm problems or history of low white blood cell counts, with your healthcare provider before starting Paliperidone Palmitate.
For the injectable form of paliperidone palmitate, there are no specific food restrictions. Unlike the oral extended-release tablets (Invega), which must be taken with or without food consistently, the absorption of the palmitate ester from the muscle is not influenced by the contents of the stomach. However, patients should maintain a healthy diet to manage potential weight gain and metabolic changes associated with the drug.
Paliperidone palmitate does not typically interfere with common laboratory tests, but it can cause physiological changes that reflect in lab results:
For each major interaction, the mechanism often involves either pharmacodynamic competition (blocking the same receptors) or pharmacokinetic changes (altering how the body processes the drug). Management strategies usually involve dose titration, frequent monitoring of vital signs, or selecting alternative medications that do not share the same side effect profile.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter cold medicines and sleep aids.
Because paliperidone is the active metabolite of risperidone, there is a high likelihood of cross-sensitivity. If a patient has had a severe allergic reaction to Risperdal (risperidone), they must not be given paliperidone palmitate. Healthcare providers will typically perform a trial with oral paliperidone or risperidone before administering the long-acting injection to ensure the patient tolerates the compound.
> Important: Your healthcare provider will evaluate your complete medical history, including any previous reactions to antipsychotic medications, before prescribing Paliperidone Palmitate.
Safety and effectiveness of paliperidone palmitate in patients under 18 years of age have not been established for schizoaffective disorder. For schizophrenia, while oral paliperidone is approved for adolescents (ages 12-17), the injectable forms are generally reserved for adults due to the complexity of dosing and the lack of long-term safety data in developing children. Long-term effects on growth and sexual maturation (due to prolactin elevation) are significant concerns in this population.
Clinical studies of paliperidone palmitate did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. However, geriatric patients are at a higher risk for:
Renal function must be assessed before starting paliperidone palmitate.
In patients with mild to moderate hepatic impairment, no dosage adjustment is required. Paliperidone is not significantly metabolized by the liver. However, it has not been studied in patients with severe hepatic impairment (Child-Pugh Class C), so it should be used with caution in this group.
> Important: Special populations require individualized medical assessment and frequent follow-up to ensure the safety of both the patient and, in the case of pregnancy, the developing child.
| Parameter | Value |
|---|---|
| Bioavailability | 100% (Intramuscular) |
| Protein Binding | ~74% (Albumin and alpha1-acid glycoprotein) |
| Half-life | 25–49 days (Monthly formulation) |
| Tmax | ~13 days (Monthly formulation) |
| Metabolism | Minimal (Not primarily CYP450 dependent) |
| Excretion | Renal 80%, Fecal 11% |
Paliperidone palmitate is classified as an atypical antipsychotic (second-generation). It is part of the benzisoxazole class, which also includes its parent drug, risperidone. Compared to other atypical antipsychotics like olanzapine or quetiapine, paliperidone is unique in its heavy reliance on renal excretion and its availability in ultra-long-acting injectable formulations.